House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.
US lawmakers are demanding answers from the Food and Drug Administration about a shortage of infant formula products as demand for production by other firms grows following the closing of an Abbott Nutrition plant due to contamination concerns.
House Appropriations and Energy and Commerce subcommittee members also will ask about the recall by the Abbott Laboratories Ltd....
Create an account to read this article
Already a subscriber?
Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.
White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.
The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful
FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.
Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.
The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful
FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.
